We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+0.05%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$3.55B
AUM Growth
+$59.4M
Cap. Flow
+$77M
Cap. Flow %
2.17%
Top 10 Hldgs %
49.57%
Holding
665
New
156
Increased
155
Reduced
111
Closed
128

Top Buys

Rank Stock Value
1
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$138M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$131M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$127M
4
MRO
Marathon Oil Corporation
MRO
+$123M
5
CHX
ChampionX
CHX
+$98.3M

Top Sells

Rank Stock Value
1
PXD
Pioneer Natural Resource Co.
PXD
+$638M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$51.2M
3
DFS
Discover Financial Services
DFS
+$45.1M
4
SCRM
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
+$18.4M
5
NSC icon
Norfolk Southern
NSC
+$17.7M

Sector Composition

Rank Sector Weight
1 Energy 26.53%
2 Technology 21.03%
3 Healthcare 14.68%
4 Industrials 8.19%
5 Materials 6.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AAPL icon
526
CALL
Apple
AAPL
$4.58T
– –
-50,000
Closed -$169K
AAPL icon
527
PUT
Apple
AAPL
$4.58T
– –
-50,000
Closed -$220K
ADBE icon
528
Adobe
ADBE
$105B
– –
-18,797
Closed -$9.48M
AFMD
529
DELISTED
Affimed
AFMD
– –
-19,071
Closed -$101K
AMCX icon
530
PUT
AMC Global Media
AMCX
$488M
– –
-50,000
Closed -$215K
AMD icon
531
Advanced Micro Devices
AMD
$788B
– –
-9,624
Closed -$1.74M
ANNX icon
532
CALL
Annexon
ANNX
$888M
– –
-418,500
Closed -$532K
ATXS
533
PUT
DELISTED
Astria Therapeutics
ATXS
– –
-90,000
Closed -$13.5K
AUTL
534
Autolus Therapeutics
AUTL
$564M
– –
-155,857
Closed -$994K
AZN icon
535
AstraZeneca
AZN
$250B
– –
-27,142
Closed -$4.08M
BA icon
536
CALL
Boeing
BA
$185B
– –
-20,000
Closed -$2.6K
BALL icon
537
Ball Corp
BALL
$16.8B
– –
-94,840
Closed -$6.39M
BCAB icon
538
BioAtla
BCAB
$5.63M
– –
-4,195
Closed -$722K
BCRX icon
539
BioCryst Pharmaceuticals
BCRX
$2.39B
– –
-32,630
Closed -$166K
BCYC
540
CALL
Bicycle Therapeutics
BCYC
$292M
– –
-70,000
Closed -$130K
BE icon
541
Bloom Energy
BE
$64.6B
– –
-250,000
Closed -$2.81M
BHVN icon
542
CALL
Biohaven
BHVN
$2.22B
– –
-23,000
Closed -$110K
BIDU icon
543
Baidu
BIDU
$37.2B
– –
-137,500
Closed -$14.5M
BIIB icon
544
CALL
Biogen
BIIB
$30.7B
– –
-18,000
Closed -$33.3K
BIIB icon
545
Biogen
BIIB
$30.7B
– –
-2,500
Closed -$539K
BMBL icon
546
Bumble
BMBL
$369M
– –
-75,000
Closed -$851K
CHGG icon
547
Chegg
CHGG
$102M
– –
-12,500
Closed -$94.6K
COGT icon
548
Cogent Biosciences
COGT
$7.23B
– –
-22,442
Closed -$151K
CPNG icon
549
Coupang
CPNG
$29.2B
– –
-30,000
Closed -$534K
CRBP icon
550
Corbus Pharmaceuticals
CRBP
$189M
– –
-7,500
Closed -$294K
20 21
22
23 24

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return

UBS O'Connor's Q2 2024 Portfolio in Review

As of Q2 2024, UBS O'Connor held 665 positions worth $3.55B, up 1.7% from $3.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

UBS O'Connor's Q2 2024 filing shows 156 new, 155 increased, 111 reduced and 128 closed positions. Its largest new stake was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M. The largest sale was Pioneer Natural Resource Co., an estimated $638M.

By sector, the portfolio is most concentrated in Energy at 27% of assets, down from 34% a quarter earlier, followed by Technology and Healthcare.

  • UBS O'Connor's largest Q2 2024 buy was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M.
  • UBS O'Connor added most to HashiCorp, Inc. Class A Common Stock in Q2 2024, an estimated $138M increase.
  • UBS O'Connor's biggest Q2 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $51.2M.
  • UBS O'Connor fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $638M.
  • UBS O'Connor's ten largest holdings make up 50% of its $3.55B portfolio in Q2 2024.
  • UBS O'Connor opened 156 new positions and closed 128 in Q2 2024.
  • UBS O'Connor's portfolio value rose 1.7% quarter-over-quarter to $3.55B.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.